Home › Funds › Rhenman & Partners Asset Management AB › BIIB

Rhenman & Partners Asset Management AB position in BIIB

BIOGEN INC · Health Care

Rhenman & Partners Asset Management AB reported holding 97,050 shares of BIIB (BIOGEN INC) in its Q3 2026 13F filing — a position valued at US$21.9M, representing 2.43% of its reported portfolio and ranking #10 among its reported holdings. Rhenman & Partners Asset Management AB has disclosed BIIB holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)97.05K sh
Reported value held$21.92M
Portfolio Weight2.43%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Rhenman & Partners Asset Management AB's BIIB position evolved

Rhenman & Partners Asset Management AB first disclosed a stake in BIIB in Q3 2023 at 56,500 shares (US$14.5M). The position peaked in Q3 2026 at 97,050 shares, worth US$21.9M. Across 13 filings, Rhenman & Partners Asset Management AB increased the stake 7 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 97,050 shares valued at US$21.9M — an increase of 2,200 shares quarter over quarter.. Notable position changes include a 84% increase in Q4 2024 (shares fell 11% over the following quarter), a 76% trim in Q2 2025 (shares rose 12% over the following quarter), a 358% increase in Q3 2025 (shares rose 26% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 56.50K $14.52M New
Q4 2023 58.67K $15.18M Add
Q1 2024 56.80K $12.25M Reduce
Q2 2024 84.80K $19.66M Add
Q3 2024 67.10K $13.01M Reduce
Q4 2024 123.70K $18.92M Add
Q1 2025 49.50K $6.77M Reduce
Q2 2025 12.00K $1.51M Reduce
Q3 2025 55.00K $7.70M Add
Q4 2025 92.35K $16.25M Add
Q1 2026 109.10K $20.00M Add
Q2 2026 94.85K $20.49M Reduce
Q3 2026 97.05K $21.92M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BIIB and 13F data

BIIB (BIOGEN INC) is a Health Care company. 20 other funds we track also report a position in BIIB — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$3.43B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BIIB

All BIIB fund holders →

FAQ

How long has Rhenman & Partners Asset Management AB held BIIB?

Rhenman & Partners Asset Management AB has disclosed BIIB holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Rhenman & Partners Asset Management AB's current position in BIIB?

As of Q3 2026, Rhenman & Partners Asset Management AB holds 97.05K shares of BIIB (BIOGEN INC), valued at $21.92M, representing 2.43% of its reported portfolio and ranking #10.

Has Rhenman & Partners Asset Management AB been buying or selling BIIB?

In the latest 13F filing (Q3 2026), Rhenman & Partners Asset Management AB increased its position in BIIB. The position peaked in Q3 2026 at 97.05K shares.

Which other funds hold BIIB?

Other major institutional holders of BIIB include PRIMECAP MANAGEMENT CO/CA/, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.